

06 Jun 2021 |

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Five Must-Know Things: a pioneering KRAS inhibitor approval; Organon's CEO on the company's plans; Astellas's mid-term ambitions; trial disappointment for Novartis's Beovu; and Indian plans for a pediatric COVID vaccine.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 4 June 2021, including: a pioneering KRAS inhibitor approval; [Organon's](#) CEO on the company's plans; [Astellas Pharma, Inc.](#)'s mid-term ambitions; trial disappointment for [Novartis AG's](#) Beovu; and Indian plans for a pediatric COVID vaccine.

These and all other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#) and [TuneIn](#) - and also now on [Spotify Podcasts](#) - and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Amgen Wins World-First Lumakras Approval, Faces Challenge Of COVID-Era Launch](#)" - Scrip, 28 May, 2021.)

(Also see "[Organon Is Serious About Building A Women's Health Company, Deal By Deal](#)" - Scrip, 3 Jun, 2021.)

(Also see "[Astellas Eyes Doubling Market Cap On Core, Focus Assets](#)" - Scrip, 1 Jun, 2021.)

(Also see "[Blow For Novartis Eye Drug Beovu As Studies Stop On Safety Worries](#)" - Scrip, 1 Jun, 2021.)

(Also see "[Can Zydus Cadila's COVID-19 Vaccine Win First Pediatric Approval In India?](#)" - Scrip, 2

Jun, 2021.)

[Click here to explore this interactive content online](#) 